Camrelizumab-induced immune-related toxic epidermal necrolysis in lung adenocarcinoma: a case report and literature review

Camrelizumab-induced immune-related toxic epidermal necrolysis in lung adenocarcinoma: a case report and literature review

Toxic epidermal necrolysis (TEN) is a rare and serious skin reaction. This study reports a case of a patient with lung adenocarcinoma (LUAD) who developed severe TEN after 8 days of treatment with Camrelizumab monotherapy. The patient’s condition was effectively relieved with high-dose corticosteroi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Man Sun, Huan Zhou, Dan Zang, Chen-Guang Liu, Jun Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Oncology
Subjects:	lung adenocarcinoma camrelizumab immune-related adverse events toxic epidermal necrolysis drug adverse reactions
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1417936/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum for the rheumatologist
by: Jyoti Ranjan Parida, et al.
Published: (2019-01-01)

Palbociclib-induced Toxic Epidermal Necrolysis: A Case Report with Review of All Cases Secondary to Cyclin-dependent Kinase 4/6 Inhibitors
by: Aurore Devoldere, et al.
Published: (2025-01-01)

Clinico- Therapeutic Study of Stevens Johnson Syndrome-Toxic Epidermal Necrolysis and Prognostic Significance of SCORTEN in Indian Patients
by: Neha Chetan Jangid, et al.
Published: (2024-01-01)

Epidemiological Characteristics and Prognostic Scoring in Toxic Epidermal Necrolysis and Stevens–Johnson Syndrome: Insights from a 17-Year Burn Center Experience
by: David Breidung, et al.
Published: (2025-01-01)

Toxic epidermal necrolysis induced by moxifloxacin and exacerbated by clindamycin in an elderly patient: A case report
by: Yongguang Wang, et al.
Published: (2025-02-01)

Toxic epidermal necrolysis with thrombocytopenia induced by intravenous immunoglobulin: a case report and mini review
by: Yoshihiro Nishita, et al.
Published: (2025-01-01)

Case report: Toxic epidermal necrolysis as a unique presentation of acute graft versus host disease in a pediatric patient
by: Elizabeth Marlowe, et al.
Published: (2025-01-01)

Toxic epidermal necrolysis induced by nivolumab therapy for unresectable intraperitoneal cancer
by: Hiroyoshi Nozaki, et al.
Published: (2025-01-01)

Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
by: Yinfang Gu, et al.
Published: (2025-02-01)

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-01-01)

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-02-01)

Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS
by: Ganggang Wang, et al.
Published: (2025-01-01)

Drug-induced urinary retention: a real-world pharmacovigilance study using FDA and Canada vigilance databases
by: Xianyu Dai, et al.
Published: (2025-01-01)

Brodalumab: Six-Year US Pharmacovigilance Report
by: Mark G. Lebwohl, et al.
Published: (2024-11-01)

Risk Stratification and Adjuvant Chemotherapy for High‐Risk Stage IA Lung Adenocarcinoma: The Unmet Needs
by: Chen Shen, et al.
Published: (2025-01-01)

Review: performance of jujube and its extracts in cancer: therapeutic, toxicity-reducing and potentiating effects
by: Boyun Gou, et al.
Published: (2025-01-01)

PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials
by: Samuel Pratama, et al.
Published: (2024-01-01)

Precision Adverse Drug Reactions Prediction with Heterogeneous Graph Neural Network
by: Yang Gao, et al.
Published: (2025-01-01)

Cabozantinib Cutaneous Toxicity—Comprehensive Review
by: Cristina Violeta Tutunaru, et al.
Published: (2025-01-01)

PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
by: Kurnia Penta Seputra, et al.
Published: (2025-01-01)

Therapeutic Levels of Acetaminophen Causing AKI: A Case Report and Literature Review
by: Hamnah Tayyab, et al.
Published: (2025-01-01)

Colorectal Metastasis From Lung Adenocarcinoma With Initial Gastrointestinal Symptoms: A Case Report and Literature Review
by: Yu Xin, et al.
Published: (2025-01-01)

Adverse events in the nervous system associated with blinatumomab: a real-world study
by: Wen Gao, et al.
Published: (2025-02-01)

Analysis of ADR reports of cetuximab based on the FDA adverse event reporting system database
by: Shuai Zhao, et al.
Published: (2025-02-01)

Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report
by: Ming-xing Wang, et al.
Published: (2025-01-01)

Challenges in setting up the antiretroviral paediatric registry in South Africa: Lessons learned from Free State Province clinics
by: B R Omotoso, et al.
Published: (2024-07-01)

Isoniazid-induced Tenosynovitis: A Rare Case Report
by: Piyush Kumar Jain, et al.
Published: (2024-12-01)

A decade-long overview of adverse events in a tertiary surgical service in South Africa
by: H Wain, et al.
Published: (2024-10-01)

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
by: Ruichen Gao, et al.
Published: (2025-02-01)

Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
by: Chuang Yang, et al.
Published: (2025-02-01)

Safety of palliative cancer patients using morphine for pain control: scoping review
by: Janillê Luciana Araújo, et al.
Published: (2025-01-01)

Adverse outcome pathway-based assessment of pulmonary toxicity from the in vivo mixture of biocides dinotefuran and cetylpyridinium chloride
by: Yoon Cho, et al.
Published: (2025-01-01)

Efficacy and safety of neoadjuvant chemoimmunotherapy and chemotherapy in patients with potentially resectable stage IIIA/IIIB NSCLC: a retrospective study
by: Yuchen Wang, et al.
Published: (2025-01-01)

Lamotrigine-Related Skin Rash
by: J. Jokubaitė, et al.
Published: (2023-12-01)

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
by: Jeanneth Elizabeth Jami Carrera, et al.
Published: (2024-11-01)

Analysis of the effectiveness of premedication in preventing early adverse reactions to antivenom serum from 2017 to 2021: A cohort study
by: Gustavo Abud Priedols, et al.
Published: (2025-01-01)

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01)

Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity
by: Miro Saarela, et al.
Published: (2025-01-01)

Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system
by: Jingrong Yang, et al.
Published: (2025-01-01)

Efficacy and Safety of Osteoporosis Medication in Renal Transplantation: A Systematic Review and Meta-Analysis
by: Amir Sheikholeslami, et al.
Published: (2024-09-01)